AMGN slides as selloff dominates the short-term trend

Traders Union
All News
Stocks
Amgen drops 9.19% today after trial news

Highlights

Amgen reported its Phase 3 DeLLphi-305 trial for IMDELLTRA in small cell lung cancer achieved a statistically significant overall survival benefit.
The late-stage trial success adds to Amgen's clinical pipeline and could strengthen future revenue, though macro uncertainty persists in the sector.
Shares of Amgen fell 9.19% to $397.01 on strong selling pressure, with technicals signaling a bearish bias and expected to trade between $392.84 and $401.18 in the next several days.

Late-stage trial success moderates as sector volatility weighs on shares

Amgen reported that its Phase 3 DeLLphi-305 trial for IMDELLTRA in small cell lung cancer achieved a statistically significant improvement in overall survival, representing a notable late-stage development for its clinical pipeline, according to Finance Yahoo. The clinical validation enhances potential future revenue streams but arrives against a backdrop of broad uncertainty following peer industry developments. Despite this positive trial outcome, price action has remained under broader selling pressure.

Bearish momentum confirmed as multiple technical signals weaken

On the H1 chart, AMGN is trading below its MA-20 at $438.02 and MA-50 at $435.77, while still sitting above the MA-200 at $358.44 on the daily timeframe. The Ichimoku Kijun level at $422.01 is functioning as immediate resistance. Momentum signals remain weak: both MACD and ADX are on sell settings, with RSI, Stochastic RSI, and CCI all deeply oversold. Bull/Bear Power confirms sustained intraday downside, and the Awesome Oscillator also strongly supports a bearish momentum bias. No internal divergence is visible between price and momentum, and recent trading ended near session lows.

Extended downside risk as low breakout odds define outlook

Over the next several days, AMGN is forecast to trade in a typical volatility band between $392.84 and $401.18. The probability of a move higher is relatively low at 22%, while a continued decline is significantly more likely at 78%. The baseline scenario is for sideways fluctuations within this corridor. A bullish scenario would need a decisive break above the $422.01 resistance, while a bearish extension may develop if AMGN breaches projected support, triggering further pullback.

Viktoras Karapetjanc, expert at Traders Union, sees Amgen as fundamentally resilient despite the recent sharp decline. He believes the robust Phase 3 IMDELLTRA trial data reinforces long-term growth prospects for the company. However, market sentiment is dampened by industry uncertainty and ongoing technical weakness below key resistance. The near-term pattern favors continued caution unless a reversal develops above $422.01. "Positive clinical momentum is building for Amgen, but patience is still required before buyers regain control."

Previously it was reported that Amgen achieved a key clinical milestone in small cell lung cancer with its DLL3-targeting therapy marking a significant advancement in its pipeline. The current technical setup now highlights a prevailing risk of further downside, with traders advised to monitor for a breach below $392.84 as an early signal of additional selling pressure.

Source of Data: AMGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.